Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol

Sponsor
University of California, San Diego (Other)
Overall Status
Recruiting
CT.gov ID
NCT04912089
Collaborator
(none)
65
1
3
18.5
3.5

Study Details

Study Description

Brief Summary

The proposed project aims to test the cognitive and neural effects of a cognitive training in a sample of individuals seeking treatment for anxiety, depression, or traumatic stress symptoms. Participants will be randomly assigned to a high dose, low dose, or assessment only condition. Participants will be compared on cognitive performance and brain response during cognitive tasks from baseline to post-treatment.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: COGENT
N/A

Detailed Description

Mood, anxiety, and traumatic stress disorders are common psychiatric conditions - affecting over 40 million U.S. adults - and are leading causes of disability worldwide. People with these conditions are commonly plagued by difficulty controlling distressing personal thoughts and memories, collectively referred to as repetitive negative thinking symptoms. Models suggest that repetitive negative thinking is driven by executive functioning deficits, such that cognitive resources are insufficient to downregulate unwanted thoughts. Executive functioning deficits could be a promising treatment target but are not typically addressed with existing interventions. The long-term goal advanced by this project is to develop effective, mechanistic cognitive training programs that can improve cognition and reduce symptoms associated with mood, anxiety, and traumatic stress disorders. The objectives of this proposal are first to determine the optimal dose of a cognitive training program designed to improve executive functioning in this population using behavioral and neural outcomes. The central hypothesis is that repeated training exercises will enhance executive functioning and will lead to a reduction of repetitive negative thinking in mood, anxiety, and traumatic stress disorders. The project will randomize participants with depression, anxiety, and/or traumatic stress disorders to one of two doses of cognitive training or a no-treatment control condition. The investigators will examine executive functioning change with cognitive task performance and functional neuroimaging assessments.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
65 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol Using Computer-based Training
Actual Study Start Date :
Oct 15, 2021
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
May 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cognitive Training Low Dose

Cognitive training completed for 8 sessions

Behavioral: COGENT
COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.

Experimental: Cognitive Training High Dose

Cognitive training completed for 16 sessions

Behavioral: COGENT
COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.

No Intervention: Repeat Assessment

Outcome Measures

Primary Outcome Measures

  1. Change in cognitive performance [Baseline, Week 4]

    Span Working Memory Score. Scores are calculated based on memory accuracy total points across all trials, with higher scores indicating better performance.

Secondary Outcome Measures

  1. Reading Span Blood Oxygen Level Dependent (BOLD) Response [Baseline, Week 4]

    Functional Magnetic Resonance Imaging (fMRI) Reading span working memory capacity task while undergoing functional MRI. Neural activation to task condition is measured using % signal change (0-100) with higher scores indicating greater activation.

  2. Emotional Working Memory Blood Oxygen Level Dependent (BOLD) Response [Week 4]

    Functional Magnetic Resonance Imaging (fMRI) emotional working memory capacity task while undergoing functional MRI. Neural activation to task condition is measured using % signal change (0-100) with higher scores indicating greater activation.

  3. Neuropsychological Performance [Baseline, Week 4]

    Change from baseline in neuropsychological performance as measured by the following tests: Flanker Inhibitory Control and Attention Test, Picture Sequence Memory Test, List Sorting Working Memory Test, Oral Reading Recognition Test, Dimensional Change Card Sort Test, Pattern Comparison Processing Speed Test, Matrix Reasoning, Digit Span, Trail Making Test, Digit Symbol Matching.

  4. Anxiety Symptoms [Baseline, Week 4]

    Change from baseline in anxiety symptoms as measured by General Anxiety Disorder 7 (GAD-7). The total score ranges from 0-21. With higher scores indicating higher levels of anxiety symptoms.

  5. Symptoms of Depression [Baseline, Week 4]

    Change from baseline in symptoms of depression as measured by the PhenX Depression-Quick Inventory of Depressive Symptoms (QUIDS). The total score ranges from 0-27, with higher scores indicating higher depressive symptoms.

  6. PTSD Symptoms [Baseline, Week 4]

    Change from baseline in PTSD symptoms as measured by PTSD Checklist for DSM-5 (PCL-5).The total score ranges from 0-80, with higher scores indicating higher severity.

  7. Repetitive Negative Thinking (RNT) [Baseline, Week 4]

    Change from baseline in RNT as measured by the Ruminative Response Scale (RRS), Penn State Worry Questionnaire (PSWQ), the Repetitive Negative Thinking Questionnaire-10 (RTQ-10) and the Perseverative Thinking Questionnaire (PTQ). The total score for the RRS ranges from 22 to 88, with higher scores indicating higher degrees of ruminative symptoms. The total score for the PSWQ ranges from 16 to 80, with higher scores indicating higher worry. The total score for the RTQ-10 ranges from 10 to 50, with higher scores indicating higher repetitive thinking. The total score for the PTQ ranges from 0 to 60, with higher scores indicating higher repetitive negative thinking. Scores of each characteristic of RNT can also be obtained.

  8. Self-reported attention Attention [Baseline, Week 4]

    Change from baseline in attention focusing and attention shifting as measured by the Attention Control Questionnaire. The total score ranges from 20 to 80, with higher scores indicating higher levels of attention control.

  9. Emotion Regulation [Baseline, Week 4]

    Change from baseline in emotion regulation tendencies as measured by the Emotion Regulation Questionnaire (ERQ). Scores are obtained by averaging the scores of two subscales: cognitive reappraisal and expressive suppression. Higher scores indicating higher use of emotion regulation.

  10. Disability [Baseline, Week 4]

    Change from baseline in disability across six domains, understanding and communicating, getting around, self-care, getting along with people, life activities, and participation in society as measured by the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0). A simple score for the WHODAS 2.0 ranges from 36-180 with higher scores indicating the degree of functional limitations. An item-response-theory based score can also be obtained by summing the recoded item scores within each of the six domains, summing the domains, and converting the summary score into a metric ranging from 0 to 100, with higher scores indicating higher disability.

  11. Suicide Cognitions [Baseline, Week 4]

    Change from baseline in suicide-related beliefs as measures by the Suicide Cognitions Scale-Revised (SCS-R). The total score ranges from 0 to 64, with higher scores indicating higher severity of suicidal cognitions.

  12. Alcohol Use [Baseline, Week 4]

    Change from baseline in drinking patterns as measured by the Alcohol Use Disorders Identification Test (AUDIT). The total score ranges from 0 to 40, with higher scores indicating higher risk. Such that 1-7 indicates low risk, 8-12 risky, and 13+ high risk.

  13. Drug Abuse [Baseline, Week 4]

    Change from baseline in drug abuse as measured by the Drug Abuse Screening Test (DAST-10). The total score ranges from 0-10, with higher scores indicating higher degree of drug abuse related problems.

  14. Insomnia [Baseline, Week 4]

    Changes from baseline in insomnia problems as measured by the Insomnia Severity Index (ISI). The total score ranges 0-21, with higher scores indicating severity of insomnia.

  15. Mood and Emotions [Baseline, Week 4]

    Changes from baseline in mood and emotions as measured by the Positive and Negative Affect Schedule (PANAS).There are two scores calculated, one for positive affect and one for negative affect. The total score for positive affect ranges from 10 to 50. The total score for negative affect ranges from 11 to 55.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • age 21-55

  • fluent in English

  • diagnosis of mood, anxiety, or traumatic stress disorder

  • clinically elevated repetitive negative thinking

  • outpatient status

  • 6-week stability if taking selective serotonin reuptake inhibitor (SSRI) medications

Exclusion Criteria:
  • past year diagnosis of severe alcohol or moderate or greater substance use disorder

  • lifetime history of psychotic or bipolar I disorder

  • acute suicidality necessitating immediate clinical intervention

  • neurodegenerative or neurodevelopmental disorders

  • history of moderate or severe traumatic brain injury or other known neurological condition

  • sensory deficits that would preclude completing tasks

  • conditions unsafe for completing MRI scanning (e.g., metal in body)

  • currently receiving psychosocial treatment

  • currently receiving psychiatric pharmacotherapy, except SSRIs

Contacts and Locations

Locations

Site City State Country Postal Code
1 UC San Diego San Diego California United States 92037

Sponsors and Collaborators

  • University of California, San Diego

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jessica Bomyea, Assistant Professor, University of California, San Diego
ClinicalTrials.gov Identifier:
NCT04912089
Other Study ID Numbers:
  • 210686
First Posted:
Jun 3, 2021
Last Update Posted:
Apr 4, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 4, 2022